Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment.

1 Sep 2016

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.

29 Aug 2016

Scientists identify eight cancer types linked to excess weight and obesity

There's yet another reason to maintain a healthy weight as we age. An international team of researchers has identified eight additional types of cancer linked to excess weight and obesity: stomach, liver, gall bladder, pancreas, ovary, meningioma (a type of brain tumor), thyroid cancer and the blood cancer multiple myeloma.

25 Aug 2016

Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

Advances in the treatment of multiple myeloma, a cancer that forms in a type of white blood cell, have led to improved survival predominantly among young and white patients, with less of an increase in survival observed in patients of other ethnicities.

22 Aug 2016

MGH investigators discover key molecules essential for sensing proteasome dysfunction

Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new proteins.

16 Aug 2016

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).

12 Aug 2016

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.

11 Aug 2016

New class of anti-cancer agents may be promising treatment for multiple myeloma

Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer.

8 Aug 2016

Abingdon Health declares FDA registration and CE marking of new ADxLR5 lateral flow device reader

Abingdon Health are pleased to announce the CE marking and FDA registration of their newly available immunoassay reader - ADxLR5 as a Class 1 Medical Device.

30 Jul 2016

Abingdon Health gains TGA regulatory approval for Seralite- FLC product in Australia

Abingdon Health Ltd, is pleased to announce that it has gained regulatory approval by the Therapeutic Goods Administration in Australia for Seralite- FLC.

30 Jul 2016

Blood cancer is associated with considerably higher healthcare costs than other cancers

Health economics studies, published today in The Lancet Haematology, report that the cost of treating blood cancers is twice that for treating other cancers. This is largely because they require more complex treatment regimens that necessitate longer hospital stays.

22 Jul 2016

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis.

13 Jul 2016

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.

12 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

TUM researchers uncover molecular mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have remained unclear.

20 Jun 2016

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.

16 Jun 2016

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.

15 Jun 2016

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States.

13 Jun 2016

Carfilzomib therapy shows promise for pre-kidney transplant patients

Early findings by researchers at the University of Cincinnati College of Medicine suggest that the use of a second generation cancer drug, carfilzomib, may provide an improved approach for the reduction of antibodies in potential kidney transplant candidates.

10 Jun 2016

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD.

10 Jun 2016

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Added benefit not proven for new combination therapy in multiple myeloma

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Scientists identify eight cancer types linked to excess weight and obesity

Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

MGH investigators discover key molecules essential for sensing proteasome dysfunction

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

New class of anti-cancer agents may be promising treatment for multiple myeloma

Abingdon Health declares FDA registration and CE marking of new ADxLR5 lateral flow device reader

Abingdon Health gains TGA regulatory approval for Seralite- FLC product in Australia

Blood cancer is associated with considerably higher healthcare costs than other cancers

New treatment approach may benefit relapsed post-transplant blood cancer patients

Study shows how increase in BMI contributes to multiple myeloma growth and progression

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

TUM researchers uncover molecular mechanism of thalidomide

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

NCCN educational resources provide insight for patients with Mycosis Fungoides

Carfilzomib therapy shows promise for pre-kidney transplant patients

Researchers discover AF1q protein linked to multiple myeloma, EMD

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in